Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer

NCT02064608 | Completed Phase 1 DMC

• 2 other identifiers: CANCAP022014-000214-56
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with localised prostate cancer can be treated by radical prostatectomy (prostate gland removal surgery) or radiotherapy. Around 15% of men with prostate cancer are diagnosed with high risk disease meaning they are more likely to suffer treatment failure, disease progression and mortality. To date little progress has been made towards identifying effective treatment strategies that might delay or prevent disease recurrence in this patient population. Better identification of patients at high risk of relapse and improvements in therapy are therefore research priorities. A protein named Mammalian Target of Rapamycin (mTOR) is known to play an important role in the development of prostate cancer. mTOR forms two protein complexes (mTORC1 and mTORC2) and sends signals helping cancer cells to grow while controlling their energy use. Blocking the function of mTOR, with an inhibitor such as AZD2014, might shut down the supply of energy supply to tumour cells leading to reduced cell growth and potentially slowing the progression of the disease. The purpose of this study is to investigate the molecular pharmacology of AZD2014 treatment given to patients with prostate cancer prior to radical prostatectomy. The feasibility, safety and tolerability of a short course of AZD2014 will also be assessed.

Conditions

Prostate Cancer

Keywords

Prostate; Cancer; Prostate Cancer; High Risk; Intermediate Risk; Early disease; Neoadjuvant treatment; Radical Prostatectomy

Outcome Measures

Primary Outcomes (1)

• To measure the amount of inhibition (percentage change from baseline) in mTORC1 and mTORC2 signalling in tumour samples from men with early, high-risk prostate cancer after AZD2014 treatment

  Participants will be treated with AZD2014 for 15 days prior to radical prostatectomy surgery. To assess the amount of mTORC1 and mTORC2 inhibition caused by AZD2014 treatment, phosphorylated signalling biomarkers (namely p4EBP1, pS6 and pAKT) will be detected by immunohistochemistry and quantified. The amount of mTORC1 and mTORC2 signalling inhibition will be determined by comparison of prostate tumour biopsies taken at baseline (time of diagnosis) and following AZD2014 treatment. An intra-operative prostate biopsy will also be taken in order to evaluate variability between samples.

  2 weeks

Secondary Outcomes (2)

• To determine the incidence of adverse events due to AZD2014 given prior to radical prostatectomy

  8 weeks unless further observation is clinically indicated

• To determine the severity of adverse events due to AZD2014 prior to radical prostatectomy

  8 weeks unless further observation is clinically indicated

Other Outcomes (3)

• To determine blood plasma concentration and pharmacokinetics of AZD2014.

  Following 15 days AZD2014 treatment

• To measure the biological effects of AZD2014 treatment

  Following 15 days AZD2014 treatment

• Exploratory endpoints

  Following 15 days AZD2014 treatment

Study Arms (1)

AZD2014

EXPERIMENTAL

This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.

Drug: AZD2014

Interventions

AZD2014 DRUG

mTOR inhibitor

Also known as: AZ12729279

AZD2014

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men aged 18 years old or older
• ECOG performance status of 0 or 1
• Clinical diagnosis of Intermediate (one or more of stage T2, or PSA \>10ng/mL, or Gleason score of at least 7) or High Risk Prostate Cancer (one or more of stage T2c, or PSA \>20ng/mL, or Gleason score of at least 8)
• Patient suitable for radical prostatectomy, following discussion at specialist MDT and subsequent review by surgical team
• Willing to use barrier contraceptive method, e.g. condom \& spermicide
• Adequate bone marrow reserve or organ function (as specified in the study protocol)
• Normal chest radiograph and oxygen saturations, OR normal CT thorax

You may not qualify if:

• Contraindication to AZD2014 (as specified in the study protocol)
• Patients who have experienced any of the following procedures in the past 12 months: coronary artery bypass graft; angioplasty; vascular stent; myocardial infarction; angina pectoris; congestive heart failure (New York Heart Association grade of 2 or above); ventricular arrhythmias requiring continuous therapy; supraventricular arrhythmias including atrial fibrillation, which are uncontrolled; haemorrhagic or thrombotic stroke including transient ischaemic attacks or any other CNS bleeding.
• Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 28 days of starting study treatment.
• Major surgery within 4 weeks prior to study entry (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study
• Potent or moderate inhibitors and inducers of CYP2C8 if taken within the stated wash-out period: Gemfibrozil, trimethoprim, glitazones, montelukast, deferasirox and quercetin (1-week minimum wash out period)
• Any haematopoietic growth factors, e.g. G-CSF, GM-CSF, within 4 weeks prior to receiving study drug
• As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (as specified in the study protocol)
• Abnormal ECHO or MUGA at baseline
• Mean resting QTc of 470msec or above (as per local reading)
• Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation, or risk of arrythmic events (examples specified in study protocol). History of Torsades de Pointes.
• Patients with Diabetes Type I or uncontrolled Type II as judged by the investigator
• Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
• Unable to provide informed consent

Sponsors & Collaborators

• Cambridge University Hospitals NHS Foundation Trust: lead
• AstraZeneca: collaborator

Study Sites (1)

Cambridge University Hospitals NHS Foundation Trust

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Location

MeSH Terms

Conditions

Prostatic Neoplasms; Neoplasms; Disease

Interventions

vistusertib

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Simon C Pacey, MRCP, PhD

  Cambridge University Hospitals NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Cambridge Clinical Trials Unit - Cancer Theme

Study Record Dates

• First Submitted: February 14, 2014
• First Posted: February 17, 2014
• Study Start: October 1, 2014
• Primary Completion: December 1, 2016
• Study Completion: June 1, 2018
• Last Updated: July 17, 2019

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)